

Vepdegestrant (vep-DEG-eh-strent), a PROTAC ER degrader, in combination with PF-07220060 in people living with ER+/HER2- advanced breast cancer

This summary contains information from the scientific poster:

TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TARgeting Chimera (PROTAC) Estrogen Receptor Degradar, in Combination with PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer

[CLICK HERE TO VIEW
THE SCIENTIFIC POSTER](#)


Copies of this poster obtained through this link are for personal use only and may not be reproduced without written permission from the authors of this poster

What is ER+/HER2- advanced breast cancer?

ER+/HER2- breast cancer is a specific type of breast cancer

- Certain types of breast cancer grow in response to **estrogen**, a hormone in the body. This is called **estrogen receptor-positive (ER+)** breast cancer
- Some types of breast cancer have a lot of a protein called **human epidermal growth factor receptor 2 (HER2)** and are called **HER2-positive (HER2+)**. Other breast cancer types have low levels or no HER2 and are called **HER2-negative (HER2-)**

Advanced breast cancer is cancer that has spread from the breast to nearby tissue (**locally advanced cancer**) or from the breast to more distant parts of the body (**metastatic cancer**)



What are some common treatments for ER+/HER2- advanced breast cancer?

Some treatments, called **endocrine therapies**, work by either blocking the body's ability to produce estrogen, or blocking the activity of estrogen in cancer cells, which may slow or stop cancer growth

- **Aromatase inhibitors**, such as letrozole, anastrozole, or exemestane, are endocrine therapies that reduce the production of estrogen
- **Fulvestrant** is an endocrine therapy that attaches to estrogen receptors and blocks their activity, which reduces estrogen's effects on tumors

Chemotherapy is a treatment that damages cancer cells. Sometimes people get chemotherapy prior to surgery to shrink the size of their tumor, after surgery to kill remaining cancer cells, or if their cancer has spread beyond the breast

CDK4/6 inhibitors are another type of treatment and work by blocking CDK4 and CDK6 proteins that cause cancer cells to grow

What is vepdegestrant?

Vepdegestrant, also called **ARV-471**, is an investigational drug taken by mouth as a pill that researchers are testing for the treatment of ER+ breast cancer. It is a **PROteolysis TARgeting Chimera (PROTAC) estrogen receptor degrader**

- PROTAC protein degraders are designed to attach to specific proteins in cells that can cause disease, which causes those proteins to be **marked for elimination** by a natural protein disposal system in the body
- Vepdegestrant works by causing **estrogen receptors to be eliminated**, which blocks the activity of estrogen and may stop ER+ breast cancer tumors from growing or cause the tumors to shrink

Why is the combination of vepdegestrant plus PF-07220060 being tested in this study?

- PF-07220060 is an investigational drug that works by blocking the action of the CDK4 protein. This may help stop certain cancers from growing
 - PF-07220060 is being studied as a treatment for ER+ breast cancer
- In laboratory research studies, vepdegestrant plus PF-07220060 **worked better at stopping cancer from being able to grow** than vepdegestrant or PF-07220060 alone

This summary describes a new clinical study to test the combination of **vepedegestrant plus PF-07220060** in people living with ER+/HER2- advanced breast cancer

The **main aims** of this study are to find out

- The side effects people who take vepdegestrant plus PF-07220060 may experience
- The best dose(s) of vepdegestrant plus PF-07220060 to use for future clinical studies
- How long people receiving these treatments live without their cancer getting worse
- The percentage of people whose cancer shrinks or disappears after treatment
- How well vepdegestrant and PF-07220060 are absorbed by the body and how long they last in the body

This study will also look at

Study Design

WHO CAN PARTICIPATE IN THE STUDY?



In part 1 of the study, people living with **ER+/HER2- advanced or metastatic breast cancer** for whom surgery is not recommended who also

- Were previously treated with **1 or more standard of care therapies for advanced or metastatic breast cancer**

In part 2 of the study, people living with **ER+/HER2- advanced or metastatic breast cancer** who also

- Were previously treated with **1 or 2 endocrine therapies** for advanced or metastatic breast cancer
- Received their most recent **endocrine therapy for at least 6 months before their disease got worse**
- Were previously treated with a **CDK4/6 inhibitor**

WHO CANNOT PARTICIPATE IN THE STUDY?



- People who are **at risk of life-threatening complications in the short term** due to their cancer
- People whose cancer **has spread to the brain and has not been treated**
- People who have **inflammatory breast cancer**

WHAT IS THE TREATMENT?

People will receive **different doses of vepdegestrant plus PF-07220060**



- Vepdegestrant will be taken as **pills by mouth once daily**
- PF-07220060 will be taken as **pills by mouth twice daily**

WHAT WILL BE MEASURED IN THE STUDY?

- The **side effects** experienced by people taking vepdegestrant plus PF-07220060
 - This includes any **symptoms** felt by the participants in the study, **signs** observed in the participants by the investigators, or **abnormalities** that are detected in the participants' blood samples or by electrocardiogram
- **Tumor size** will be measured by scans to evaluate if vepdegestrant plus PF-07220060 treatment has any effect on slowing tumor growth or shrinking tumors
- The amount of time that people **survive without their cancer getting worse**
- Levels of **vepedegestrant and PF-07220060 in the blood** will be measured to assess how the different treatments may **influence each other**

Who sponsored the study?

This study is sponsored by Pfizer, Inc. in collaboration with Arvinas Estrogen Receptor, Inc.

Pfizer, Inc.

235 East 42nd Street
New York, NY 10017

Phone (United States): +1 212-733-2323

Arvinas Estrogen Receptor, Inc.

5 Science Park
395 Winchester Ave.
New Haven, CT 06511

Phone (United States): +1 203-535-1456

Arvinas and Pfizer thank **the people who are volunteering to participate in this study** and **their caregivers**, as well as the **investigators, researchers, and coordinators** who are contributing to this study

Writing and editorial support for this summary was provided by Marita Chakhtoura, MS, PhD, of Red Nucleus, and was funded by Arvinas Operations, Inc.

Where can I find more information?

For more information on this study

[VIEW CLINICAL TRIAL RECORD](#)

For more information on clinical studies in general

[VIEW INFORMATION](#)